CD28 and cancer: Emerging evidence suggests that incorporating a third specificity, particularly targeting co-stimulatory molecules such as CD28, 4-1BB, or OX40, in addition to CD3 on T cells and a tumor-associated antigen (TAA) on cancer cells, can enhance T-cell activation and prevent exhaustion.